Tag: ASCO
ADAPT Study Shows Promising Results in the Treatment of Patients with...
Results from the German phase II ADAPT study (WSG-ADAPT), showed that neoadjuvant ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) is effective in the treatment of HER2-positive,...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...
Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...
Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer
An interim analysis of a mid-stage clinical study showed that labetuzumab govitecan, also known as (IMMU-130), a novel antibody-drug conjugates or ADC being developed by...
What to Expect at ASCO 2015?
The 51st ASCO - the Annual Meeting of the American Society of Clinical Oncology, which will take place in the McCormick Place Convention Center in Chicago, Illinois, May 29 – June 2, 2015 is expected attract more than 30,000 oncology professionals from around the world.
Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...
With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.
SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...
A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.
Results from Phase I Trial with SGN-CD19A Shows Encouraging Anti-tumor Activity...
esults from an interim phase I clinical trial presented at the 50th Annual Meeting of the American Association of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, shows that SGN-CD19A (Seattle Genetics, Inc, Bothell, WA 98021, USA), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies, offers encouraging anti-tumore activity in patients with Non-Hodgkin Lymphoma (NHL).[1]
Phase I Study of ABT-414 Shows Four Objective Responses, Including Complete...
Preliminary results from an ongoing Phase I study with the investigational compound ABT-414 (Abbvie, Inc.,North Chicago, Illinois, U.S.A.), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate or ADC, in combination with temozolomide (Temodar®; Merck & Co., Inc.) which is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment, showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiform. In separate clinical trials ABT-414 is also investigated for the treatment of patients with squamous cell tumors.
